Loading cancer entity…
Loading cancer entity…
Clinical trials
3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (571)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00279058 | The Role of Peptide-loaded Dendritic Cells to Augment the Therapeutic Effect of Interleukin-2 | completed | Phase 1 / Phase 2 | 24 | Hadassah Medical OrganizationOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00029900 | ADI-PEG in Patients With Metastatic Melanoma | completed | Phase 1 | 15 | FDA Office of Orphan Products DevelopmentFED | 1 | Mar 25, 2015 | clinicaltrials |
| NCT00668512 | Intratumoral Injection Of Alpha-Gal Glycosphingolipids | completed | Phase 1 | 12 | University of Massachusetts, WorcesterOTHER | 1 | Mar 19, 2015 | clinicaltrials |
| NCT00753415 | A Study of V934/V935 Vaccine in Cancer Participants With Selected Solid Tumors (V934-002) | completed | Phase 1 | 37 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Mar 17, 2015 | clinicaltrials |
| NCT00661336 | A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma | withdrawn | Phase 1 | 0 | Duke UniversityOTHER | 1 | Mar 13, 2015 | clinicaltrials |
| NCT01127594 | Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion | completed | Phase 1 | 29 | Douglas TylerOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT01752257 | EF5 in Melanoma Patients | completed | Phase 1 | 15 | Douglas TylerOTHER | 1 | Mar 9, 2015 | clinicaltrials |
| NCT00565968 | Sorafenib and Isolated Limb Infusion of Melphalan in Treating Patients With Stage III Melanoma of the Arm or Leg | completed | Phase 1 | 20 | Duke UniversityOTHER | 1 | Mar 6, 2015 | clinicaltrials |
| NCT00441337 | A Study of MDX-1106 in Patients With Selected Refractory or Relapsed Malignancies(MDX1106-01) | completed | Phase 1 | 39 | Bristol-Myers SquibbINDUSTRY | 1 | Feb 20, 2015 | clinicaltrials |
| NCT00412828 | A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 117 | CuraGen CorporationINDUSTRY | 1 | Feb 19, 2015 | clinicaltrials |
| NCT00124124 | Comparison of Dendritic Cells Versus Montanide as Adjuvants in a Melanoma Vaccine | completed | Phase 1 | 50 | Dr. Nina BhardwajINDIV | 1 | Feb 13, 2015 | clinicaltrials |
| NCT00085488 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | completed | Phase 1 | — | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Feb 2, 2015 | clinicaltrials |
| NCT02350972 | Inducing Systemic Immunity and Regressions in Metastatic Melanoma | completed | Phase 1 | 88 | NYU Langone HealthOTHER | 0 | Jan 30, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT01989559 | Booster Vaccination in Preventing Disease Recurrence in Previously Vaccinated Patients With Melanoma That Has Been Removed By Surgery | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Jan 26, 2015 | clinicaltrials |
| NCT01386580 | An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. | completed | Phase 1 / Phase 2 | 84 | BBB-Therapeutics B.V.INDUSTRY | 4 | Jan 22, 2015 | clinicaltrials |
| NCT01462773 | Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma | completed | Phase 1 | 16 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 13, 2015 | clinicaltrials |
| NCT01400451 | Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) | terminated | Phase 1 | 18 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 1, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00003224 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 22 | University of VirginiaOTHER | 1 | Nov 20, 2014 | clinicaltrials |
| NCT00089219 | Vaccine Therapy in Treating Patients With Stage IIIB, Stage IIIC, or Stage IV Melanoma | completed | Phase 1 / Phase 2 | 39 | University of VirginiaOTHER | 1 | Nov 20, 2014 | clinicaltrials |
| NCT01247623 | Trial With Telomerase Peptide Vaccine In Combination With Temozolomide in Patients With Advanced Malignant Melanoma | completed | Phase 1 / Phase 2 | — | Oslo University HospitalOTHER | 1 | Nov 5, 2014 | clinicaltrials |
| NCT01835184 | Cabozantinib-S-Malate and Vemurafenib in Treating Patients With Solid Tumors or Melanoma That is Metastatic or That Cannot Be Removed By Surgery | terminated | Phase 1 | 5 | National Cancer Institute (NCI)NIH | 1 | Sep 25, 2014 | clinicaltrials |
| NCT01841463 | Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation | suspended | Phase 1 | 100 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 4, 2014 | clinicaltrials |
| NCT01489059 | Safety Study of IL-21/Ipilimumab Combination in the Treatment of Melanoma | completed | Phase 1 | 42 | Bristol-Myers SquibbINDUSTRY | 2 | Aug 29, 2014 | clinicaltrials |
| NCT00710515 | Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 2 | Aug 13, 2014 | clinicaltrials |
| NCT00003750 | Biological Therapy in Treating Children With Refractory or Recurrent Neuroblastoma or Other Tumors | completed | Phase 1 | 28 | Children's Oncology GroupNETWORK | 3 | Aug 8, 2014 | clinicaltrials |
| NCT02203864 | Dose Escalation Study to Evaluate Safety and Tolerability of an Allogeneic Tumor Vaccine BIWB 2 in Patients With Advanced Malignant Melanoma | completed | Phase 1 | 49 | Boehringer IngelheimINDUSTRY | 0 | Jul 31, 2014 | clinicaltrials |
| NCT01531244 | Isolated Limb Infusion Chemotherapy With Targeted Gene Therapy for Advanced, Unresectable Extremity Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Washington University School of MedicineOTHER | 0 | Jul 18, 2014 | clinicaltrials |
| NCT01123304 | Safety Study of Human IgM (MORAb-028) to Treat Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 17, 2014 | clinicaltrials |
| NCT01212276 | A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma | terminated | Phase 1 | 18 | MorphotekINDUSTRY | 1 | Jul 16, 2014 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00920907 | Comparison of Ipilimumab Manufactured by 2 Different Processes in Participants With Advanced Melanoma | completed | Phase 1 | 99 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 20, 2014 | clinicaltrials |
| NCT00671554 | Trial of Melaxin Cancer Vaccine Plus Bacillus Calmette-Guerin (BCG) to Treat Malignant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Prisma Health-UpstateOTHER | 1 | Jun 4, 2014 | clinicaltrials |
| NCT00005841 | Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma | terminated | Phase 1 | 15 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00025181 | Monoclonal Antibody and Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Has Been Removed During Surgery | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT00028431 | Novel Adjuvants for Peptide-Based Melanoma Vaccines | completed | Phase 1 | 19 | University of Southern CaliforniaOTHER | 1 | May 22, 2014 | clinicaltrials |
| NCT01339663 | Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma | completed | Phase 1 | 12 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 21, 2014 | clinicaltrials |
| NCT00349206 | Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma | completed | Phase 1 | 69 | National Cancer Institute (NCI)NIH | 1 | Apr 10, 2014 | clinicaltrials |
| NCT01689870 | Study of the Combination of Anti-OX40 and Ipilimumab in Patients With Metastatic Melanoma | withdrawn | Phase 1 / Phase 2 | 0 | Ludwig Institute for Cancer ResearchOTHER | 0 | Apr 1, 2014 | clinicaltrials |
| NCT00356460 | Safety and Efficacy Study of GC1008 to Treat Renal Cell Carcinoma or Malignant Melanoma | completed | Phase 1 | 29 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 19, 2014 | clinicaltrials |
| NCT00084214 | STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma | completed | Phase 1 / Phase 2 | 103 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Mar 6, 2014 | clinicaltrials |
| NCT00313508 | Dendritic Cell Vaccination During Lymphoid Reconstruction | completed | Phase 1 | 18 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Feb 21, 2014 | clinicaltrials |
| NCT00012064 | Vaccine Therapy in Treating Patients With Stage IV or Recurrent Melanoma | completed | Phase 1 / Phase 2 | 56 | Lisata Therapeutics, Inc.INDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00672542 | Immunotherapy of Melanoma With Tumor Antigen RNA and Small Inhibitory RNA Transfected Autologous Dendritic Cells | completed | Phase 1 | 12 | Scott PruittOTHER | 1 | Jan 23, 2014 | clinicaltrials |
| NCT00553683 | Cyclophosphamide, Radiation Therapy, and Poly ICLC in Treating Patients With Unresectable, Recurrent, Primary, or Metastatic Liver Cancer | unknown | Phase 1 / Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Jan 14, 2014 | clinicaltrials |
| NCT00002817 | Vaccine Therapy in Treating Patients With Metastatic Melanoma | unknown | Phase 1 / Phase 2 | 30 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00538005 | Sorafenib, Bevacizumab, and Oxaliplatin in Treating Patients With Metastatic Malignant Melanoma | unknown | Phase 1 / Phase 2 | 54 | San Diego Pacific Oncology & Hematology AssociatesOTHER | 1 | Jan 10, 2014 | clinicaltrials |
| NCT00004025 | Vaccine Therapy With or Without Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma | unknown | Phase 1 / Phase 2 | 36 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Jan 6, 2014 | clinicaltrials |
Data updated 22 days agoSource updated Apr 21, 2015source: clinicaltrials